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Virtually all diabetic dogs require exogenous insulin therapy to control their 21 
hyperglycaemia. In the UK, the only licensed insulin product currently available is a purified 22 
porcine insulin preparation. Recombinant insulin is somewhat problematic in terms of its 23 
manufacture, as the gene product (preproinsulin) undergoes substantial post-translational 24 
modification in pancreatic β cells before it becomes biologically active. The aim of the present 25 
study was to develop recombinant canine single-chain insulin (SCI) analogues that could be 26 
produced in a prokaryotic expression system and which would require minimal processing. 27 
Three recombinant SCI constructs were developed in a prokaryotic expression vector, by 28 
replacing the insulin C-peptide sequence with one encoding a synthetic peptide (GGGPGKR) 29 
or with one of two insulin-like growth factor (IGF)-2 C-peptide coding sequences (human: 30 
SRVSRRSR; canine: SRVTRRSSR). Recombinant proteins were expressed in the periplasmic 31 
fraction of E. coli and assessed for their ability to bind to the insulin and IGF-1 receptors and 32 
to stimulate glucose uptake in 3T3-L1 adipocytes. 33 
 34 
All three recombinant SCI analogues demonstrated preferential binding to the insulin 35 
receptor, compared to the IGF-1 receptor, with increased binding compared to recombinant 36 
canine proinsulin. The recombinant SCI analogues stimulated glucose uptake in 3T3-L1 37 
adipocytes compared to negligible uptake using recombinant canine proinsulin, with the canine 38 
insulin/cIGF-2 chimaeric SCI analogue demonstrating the greatest effect. Thus, biologically-39 
active recombinant canine SCI analogues can be produced relatively easily in bacteria, which 40 
could potentially be used for treatment of diabetic dogs. 41 
 42 
Keywords: Insulin; Insulin receptor; Canine diabetes; Glucose uptake 43 
44 
Introduction 45 
Diabetes mellitus in dogs is characterised by the presence of hyperglycaemia caused by 46 
an absolute or relative deficiency in the pancreatic β cell hormone, insulin (Catchpole et al., 47 
2008). Virtually all diabetic dogs require administration of exogenous insulin to control their 48 
blood glucose concentration. Whereas recombinant insulin is used to treat human diabetic 49 
patients, in the UK there is currently only one licensed insulin product available for treatment 50 
of diabetes in companion animals, which consists of purified porcine insulin (Caninsulin, MSD 51 
Animal Health)1. Recombinant human insulin has been used for many years in North America 52 
for treatment of canine diabetes, where until recently there was no FDA-approved insulin for 53 
companion animals (Rucinsky et al., 2010). 54 
 55 
Production of purified beef and pork insulin has been scaled down, with the 56 
introduction of recombinant techniques for production of human insulin. Since the supply of 57 
bovine and porcine insulin for veterinary use generally relies on human market availability, 58 
insulin for diabetic dogs is likely to become increasingly limited. Indeed, in recent years, 59 
bovine insulin products (formerly Insuvet soluble, lente and protamine zinc insulin, Zoetis) 60 
have been withdrawn from the veterinary market. Thus, there is an anticipated need for 61 
development of recombinant canine insulin preparations. 62 
 63 
Biologically active insulin is synthesised in pancreatic β cells by extensive post-64 
translational modification of preproinsulin. After folding and disulphide bond formation 65 
between insulin A and B chains, cleavage of the connecting C-peptide is required for biological 66 
activity (Fig. 1A). Proinsulin demonstrates a somewhat modest 1-2% affinity for binding to the 67 
insulin receptor (INSR) compared to insulin and it is thought that there are two main reasons 68 
                                                 
1 See: http://www.vmd.defra.gov.uk/productinformationdatabase/SPC_Documents/SPC_124274.doc. 
for this (Peavy et al., 1985); insulin C-peptide does not seem to allow enough molecular 69 
flexibility to facilitate interaction with INSR binding sites and it interferes with important 70 
receptor-binding residues such as glycine at position A1. This presents a challenge for 71 
commercial production of recombinant insulin, since most methods are based on use of 72 
prokaryotic expression systems, with bacteria and yeast lacking the necessary cellular 73 
machinery and enzymes required for correct folding and processing of proinsulin to insulin. 74 
 75 
The first recombinant insulin to become commercially available (Humulin, Eli Lilly) 76 
was based on a process whereby insulin A and B chains were produced separately in bacteria, 77 
then combined to form the biologically active molecule (Riggs and Itakura, 1979). However 78 
this process is somewhat inefficient and subsequently different techniques have been employed 79 
for commercial production of recombinant human insulin, which usually involves synthesis of 80 
a precursor molecule that is subjected to chemical and/or enzymatic modification (Christensen 81 
et al., 1991). 82 
 83 
An alternative approach to synthesis of recombinant insulin is to produce single chain 84 
insulin (SCI) analogues, which do not require post-translational modification to exert their 85 
biological activity (Kristensen et al., 1995). In SCI analogues, the proinsulin C-peptide is 86 
substituted with alternative linking peptide sequences that allow folding and disulphide bond 87 
formation between A and B chains, but which do not require cleavage and interfere with 88 
binding to the INSR much less than the native C-peptide. One such construct, developed for 89 
gene therapy of diabetes, involved substituting the insulin C-peptide with a synthetic peptide 90 
linker (Lee et al., 2000). 91 
 92 
There are other members of the insulin superfamily, with the most important being the 93 
insulin-like growth factors IGF-1 and IGF-2 (Chan and Steiner, 2000). Unlike insulin, IGF-1 94 
and IGF-2 do not require cleavage of their C-peptide to bind to their cognate receptors. IGF-2 95 
has been implicated in the syndrome of non-islet cell tumour hypoglycaemia, which involves 96 
production of an IGF-2 related peptide by tumour cells that acts on insulin receptors to cause 97 
hypoglycaemia (Boari et al., 1995; LeRoith, 2004; Zini et al., 2007). Thus, insulin and IGF-2 98 
both have glucose-lowering properties that might be exploited for developing a novel 99 
therapeutic for canine diabetes. 100 
 101 
The aim of the present study was to develop canine SCI analogues, whereby the insulin 102 
C-peptide was substituted with either a synthetic peptide linker or alternatively the human or 103 
canine IGF-2 C-peptide sequence, to express these recombinant SCI analogues in bacteria and 104 
to assess their ability to bind to the INSR and stimulate glucose uptake in cultured cells. The 105 
hypothesis was that such SCI analogues would be biologically active, without any requirement 106 
for post-translational modification. 107 
 108 
Materials and methods 109 
Generation of canine single-chain insulin analogue constructs 110 
 The coding sequence for recombinant canine proinsulin (rcPROINS) was amplified by 111 
PCR with a high-fidelity proof-reading polymerase (Easy-A High-Fidelity PCR cloning kit, 112 
Stratagene) using canine insulinoma cDNA as the template. Restriction sites for EcoRI and 113 
SphI were incorporated into the forward and reverse primers respectively (see Appendix: 114 
Supplementary material) to allow for subsequent directional subcloning of rcPROINS from the 115 
pSC-A cloning vector (Stratagene) to the pTAC-MAT-Tag-2 expression vector (Sigma-116 
Aldrich). 117 
 118 
Three SCI analogues were designed, each substituting the proinsulin C-peptide with a 119 
different peptide linker sequence (Fig. 1B). The pSC-A/rcPROINS plasmid DNA was used as 120 
the template for further PCR to generate the necessary coding sequences for each of the 121 
constructs. Initially, primers designed to anneal to insulin A chain or B chain were modified by 122 
adding specific synthetic oligonucleotide sequences encoding the linking GGGPGKR peptide 123 
as well as restriction sites to facilitate ligation of the two elements into a single construct. The 124 
pTAC-MAT-Tag-2/rcINS[GGGPGKR] construct was completed by digestion of PCR 125 
products, followed by ligation into the pTAC-MAT-Tag-2 vector (see Appendix: 126 
Supplementary material for more information on cloning strategy). 127 
 128 
A synthetic oligonucleotide dimer encoding the FLAG epitope (Asp-Tyr-Lys-Asp-Asp-129 
Asp-Asp-Lys) was inserted into these two expression constructs immediately upstream of and 130 
in frame with the proinsulin coding sequence. Subsequently, pTAC-MAT-Tag-2/rcPROINS 131 
plasmid DNA was used as the template to generate amplicons required to create the canine 132 
insulin/IGF-2 C-peptide chimeric constructs, rcINS[cIGF-2C] and rcINS[hIGF-2C] (see 133 
Appendix: Supplementary material for more information on cloning strategy). Constructs were 134 
subcloned into the pFLAG-ATS (Sigma-Aldrich) periplasmic expression vector that had been 135 
modified to incorporate a 3ʹ metal affinity tag (pFLAG-MAT-Tag-ATS). Using the same 136 
methodology, the MAT sequence was also inserted into the pFLAG-ATS+BAP (bacterial 137 
alkaline phosphatase) vector (Sigma-Aldrich) to create pFLAG-MAT-Tag-ATS+BAP, used as 138 
a positive control for expression studies. Plasmid DNA was transformed into BL-21(T1) E. 139 
coli (Sigma-Aldrich) for expression of recombinant proteins. 140 
 141 
Expression of recombinant SCI analogues 142 
Expression of recombinant protein was performed in E. coli, transformed with plasmid 143 
DNA encoding rcPROINS or the various SCI analogues. An individual colony was inoculated 144 
into 10 mL LB broth containing 100 μg/mL ampicillin (LB Liquid Amp, Fermentas) and 145 
incubated in an orbital shaker at 145 rpm, 37 °C overnight. Bacterial cultures were diluted by 146 
adding 1 mL to 50 mL pre-warmed LB/Amp in a 250 mL baffled shaker flask (Erlenmeyer 147 
Culture Flask Baffled Base, BD Falcon) and incubated at 145 rpm, 37 °C until they reached 148 
the desired turbidity (optical density at 600 nm; OD600 = 2.0), as measured with an Eppendorf 149 
BioPhotometer. Isopropyl β-D-1-thiogalactopyranoside (IPTG, Sigma-Aldrich) was added to 150 
cultures at 1 mM for 4 h to stimulate recombinant protein expression. Bacterial pellets were 151 
obtained by centrifuging samples at 2500 g for 15 min. Bacteria were lysed in 10 M guanidium 152 
hydrochloride (Sigma-Aldrich) in PBS pH 7.2, centrifuged at 13,000 g for 2 min and 153 
supernatants used for analysis. Alternatively bacterial pellets from 20 mL culture were 154 
resuspended in 40 mL/g osmotic shock buffer (500 mM sucrose, 30 mM Tris-HCl, 1 mM 155 
EDTA, pH 8.0; all Sigma-Aldrich) and centrifuged at 3500 g at 10 C for 10 min. Pellets were 156 
then resuspended in 25 mL/g ice-cold distilled water, incubated for 5 min, then centrifuged at 157 
3500 g for 10 min at 4 C to obtain the periplasmic fraction. 158 
 159 
Analysis of recombinant SCI analogues by ELISA and Western blotting 160 
 Fifty microlitres of bacterial lysate were added to nickel-coated ELISA wells (Ni-NTA 161 
HisSorb strips, Qiagen) and incubated at room temperature for 2 h. After three washes with 162 
200 µL PBS supplemented with 0.1% Tween-20 (PBST), 50 µL per well of anti-FLAG M2 163 
HRP antibody conjugate (Sigma-Aldrich) diluted 1:10,000 in PBST was added and plates 164 
incubated for 1 h. After a further six washes with PBST, binding of anti-FLAG was detected 165 
by adding 50 µL per well of 3,3′,5,5′-Tetramethylbenzidine (TMB liquid substrate system for 166 
ELISA, Sigma-Aldrich) and the reaction stopped by adding 100 µL 2M sulphuric acid (SLS). 167 
The optical density at 450 nm (OD450) of each well was then measured using a SpectraMax M2 168 
microplate reader. Results are shown as the mean OD of triplicate wells, following subtraction 169 
of values for background wells containing lysis buffer only. Estimation of FLAG-tagged 170 
recombinant protein concentration in bacterial periplasmic samples was performed by 171 
reference to a standard curve, constructed using a dilution series of FLAG-BAP control protein 172 
(Sigma-Aldrich) in an anti-FLAG ELISA. 173 
 174 
 Bacterial periplasmic fractions were reduced using 10% -mercaptoethanol (Sigma-175 
Aldrich) in sodium dodecyl sulphate (SDS) buffer (RunBlue LDS sample buffer, Expedeon) 176 
for 15 min at 95 C. Denatured proteins were separated under reducing conditions using 16% 177 
PAGE gels (RunBlue Gel, Expedeon) in an X-cell SureLock Mini-cell (Invitrogen) at constant 178 
180V for 60 min. Transfer of the separated proteins to nitrocellulose membranes was performed 179 
in the X-cell II Blot module (Invitrogen) using transfer buffer (PAGEgel.com) under reducing 180 
conditions at constant 30 V for 60 min. Membranes were rinsed with PBST, blocked in PBST 181 
supplemented with 5% dried skimmed milk (Marvel, Premier International Food) overnight, 182 
then incubated for 60 min in 15 mL of anti-FLAG HRP antibody diluted 1:5000 in PBST/5% 183 
milk. Membranes were subsequently washed four times with PBST and antibody binding 184 
detected by enhanced chemiluminescence (Amersham ECL Western Blotting Detection 185 
Reagents, GE Healthcare) using autoradiography film (Amersham Hyperfilm ECL, GE 186 
Healthcare). 187 
 188 
Receptor-binding assays 189 
Flat bottomed MaxiSorp microplates (Nunc) were coated with 50 µL per well 190 
recombinant human insulin receptor (rhINSR) or IGF-1 receptor (rhIGF-1R) (R&D Systems) 191 
at 4 µg/mL and incubated overnight at 4 °C. Negative control wells contained diluent (0.15 M 192 
PBS) only. After three washes with PBST, plates were blocked with 100 µL per well PBST 193 
supplemented with 5% bovine serum albumin (BSA), incubated for 3 h and washed a further 194 
three times. Recombinant FLAG-tagged SCI analogues from bacterial periplasmic fractions 195 
were added at 50 µL per well at the indicated concentrations. Biotinylated bovine insulin 196 
(Sigma-Aldrich) or biotinylated recombinant human IGF-1 (bIGF-1; IBT Systems) were used 197 
as positive controls. Plates were incubated for 1 h prior to washing three times with PBST, then 198 
100 µL per well of anti-FLAG HRP at 1:10,000 dilution or streptavidin HRP (Sigma-Aldrich) 199 
at 1:200 dilution (both in PBST/0.1% BSA) added. Plates were incubated for 1 h, washed six 200 
times with PBST then 50 µL per well of supersensitive TMB (Sigma-Aldrich) added. The 201 
reaction was stopped by adding 100 µL 2M sulphuric acid and the absorbance at 450 nm 202 
(OD450) measured using a SpectraMax M2 microplate reader. Results were calculated as the 203 
mean OD450 of triplicate wells following subtraction of background values in the absence of 204 
receptor; binding curves were constructed and analysed according to a four-parameter logistic 205 
equation using GraphPad Prism version 5.0 for Windows. Relative binding activities were 206 
compared using one-way ANOVA, followed by the Student’s t-test with the Bonferroni post-207 
hoc correction applied (PASW Statistics for Windows). Adjusted values were considered 208 
significant at P < 0.05. 209 
 210 
Glucose uptake assay 211 
 The ability of recombinant SCI analogues to induce a biological effect was assessed by 212 
measuring insulin-stimulated glucose uptake in cultured adipocytes. This was achieved using 213 
a mouse fibroblast cell line (3T3-L1, ATCC) which were differentiated into mature adipocytes 214 
(see Appendix: Supplementary material), then cultured with a fluorescent glucose analogue, 6-215 
(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-deoxyglucose (6-NBDG), according to a 216 
previously described protocol (Jung et al., 2011). Briefly, triplicate wells of 3T3-L1 cells 217 
cultured in 24-well plates were used for experiments on days 8-15 post-induction of 218 
differentiation. Cells were cultured in serum-free, low glucose (1.5 g/L) Dulbecco’s Modified 219 
Eagles Medium (Sigma-Aldrich) for 2 h at 37 °C, 5% CO2. Following aspiration of culture 220 
medium, cells were then incubated for 1 h at 37 °C, 5% CO2, in 250 µL PBS containing 100 221 
µM 6-NBDG in the presence or absence of 5 nM porcine insulin (Sigma-Aldrich), which is 222 
identical to canine insulin, or the different recombinant SCI analogues, isolated from bacterial 223 
periplasmic fractions. Cells were washed three times with 500 µL PBS and lysed using 650 µL 224 
per well 90% dimethyl-sulfoxide. Two hundred microlitres was transferred in triplicate to black 225 
96-well plates and fluorescence measured using a SpectraMax M2 microplate reader (λex = 466 226 
nm, λem = 540 nm, cut-off = 530 nm). Fluorescence was compared between stimulated and 227 
unstimulated cells and between the different SCI analogues using one-way ANOVA, followed 228 
by the Student’s t-test with the Bonferroni post-hoc correction applied (PASW Statistics for 229 
Windows). Adjusted values were considered significant at P < 0.05. 230 
 231 
Results 232 
Characterisation of recombinant single-chain insulin analogues 233 
 All constructs (rcPROINS, rcINS[GGGPGKR], rcINS[cIGF2C] and rcINS[hIGF2C]) 234 
were confirmed by sequencing in both pTAC-MAT-Tag-2 and pFLAG-MAT-Tag-ATS 235 
expression vectors. All constructs were induced to express recombinant protein simultaneously 236 
for 4 h and ELISA of bacterial whole cell lysates demonstrated the presence of recombinant 237 
protein expressing both MAT and FLAG epitopes (Fig. 2). Since the SCI analogues were 238 
designed flanked by FLAG at the 5’ end and MAT at the 3’ end, this was evidence that 239 
recombinant protein was being expressed as anticipated, with expression from the pFLAG-240 
MAT-Tag-ATS vector greater than from the pTAC-MAT-Tag-2 vector. Western blotting was 241 
performed on the periplasmic fractions of bacteria transformed with the pFLAG-MAT-Tag-242 
ATS constructs, confirming that the recombinant proteins were of the anticipated sizes (Fig. 243 
3). 244 
 245 
Binding of recombinant SCI analogues to insulin and IGF-1 receptors 246 
 To assess differential binding of the SCI analogues to the INSR and IGF-1R, a direct 247 
ELISA was initially performed. This demonstrated that biotinylated insulin and IGF-1 248 
preferentially bound their cognate receptors (Fig. 4A). Although rcPROINS showed a degree 249 
of binding to the INSR and IGF-1R, binding to the INSR was greater and more selective, 250 
compared to binding to IGF-1R for the three SCI analogues assessed (Fig. 4A). Comparing the 251 
relative binding for ligands to rhINSR and rhIGF-1R, revealed ratios of 1.6:1 for rcPROINS, 252 
4.9:1 for rcINS[GGGPGKR], 3.1:1 for rcINS[cIGF-2C] and 4.9:1 for rcINS[hIGF-2C], 253 
compared to 5.5:1 for insulin and 0.17:1 for IGF-1. 254 
 255 
Dose-response curves for binding of each recombinant protein to rhINSR demonstrated 256 
that saturation was reached at approximately 5 nM (Fig. 4B). The dose-response curve for 257 
rcPROINS was shifted to the right, whilst the curves for all SCI analogues were similar. A 258 
competitive-inhibition ELISA against biotinylated insulin was performed to obtain 259 
comparative IC50 values for the binding of each rcINS to the insulin receptor (Fig. 4C). It was 260 
not possible to obtain an IC50 value for rcPROINS, since sufficient inhibition of the signal 261 
could not be achieved with the maximum concentration of recombinant protein available. The 262 
relative IC50 values for rcINS[cIGF-2C] and for rcINS[hIGF-2C] were similar, at 593 pM and 263 
613 pM respectively. The lowest IC50 was demonstrated by rcINS[GGGPGKR], at 187 pM, 264 
suggesting a higher affinity for the insulin receptor compared to the rcINS[IGF-2C] constructs. 265 
 266 
Stimulation of glucose uptake by recombinant SCI analogues 267 
 Fluorescent glucose uptake was not significantly different comparing unstimulated 268 
cells to cells incubated with rcPROINS (Fig. 5). In contrast, fluorescent glucose uptake by cells 269 
incubated with porcine insulin, rcINS[GGGPGKR], rcINS[cIGF-2C] and rcINS[hIGF-2C] was 270 
significantly greater than in unstimulated cells (P < 0.05). While cells cultured with each SCI 271 
analogue demonstrated significantly greater fluorescence than with rcPROINS (P < 0.05), there 272 
was no significant difference comparing the three different recombinant SCI analogues. 273 
 274 
Discussion 275 
 The present study developed a number of plasmid DNA constructs that could be used 276 
for prokaryotic expression of recombinant SCI analogues, where the insulin C-peptide was 277 
replaced with either a synthetic linker, canine IGF-2 C-peptide or human IGF2-C peptide. 278 
These SCI analogues were shown to be capable of binding to the INSR and stimulating glucose 279 
uptake in vitro. 280 
 281 
 Recombinant proteins produced in this study were expressed as epitope-tagged fusion 282 
proteins. Prokaryotic vectors were selected that produced recombinant proteins with a C-283 
terminal metal-affinity tag. Such epitope-tagged recombinant proteins can be immobilised 284 
using metals such as nickel, which is useful for both detection and purification. A FLAG 285 
epitope was inserted upstream of the B-chain coding sequence, which also possessed an 286 
enterokinase cleavage site immediately before the start of the B-chain, so that this epitope could 287 
potentially be removed, if the presence of the FLAG peptide inhibited receptor binding. 288 
 289 
Expression of each construct was assessed by both ELISA and Western blotting, 290 
demonstrating that recombinant proteins of the appropriate sizes were produced from both 291 
pTAC-MAT-Tag-2 and pFLAG-MAT-Tag-ATS vectors in E. coli. Expression from pTAC-292 
MAT-Tag-2 resulted in production of recombinant protein for each rcINS construct, although 293 
subsequent work demonstrated that this was primarily in the insoluble fraction (data not 294 
shown). Expression of recombinant protein in E. coli commonly results in aggregation and 295 
formation of inclusion bodies (Thomas and Baneyx, 1996). The reducing environment of the 296 
bacterial cytosol does not favour folding of eukaryotic protein, especially those reliant on 297 
disulphide bond formation (Mergulhao et al., 2004), such as insulin (Williams et al., 1982). 298 
 299 
Unlike the bacterial cytosol, the periplasm (the space between the inner cytoplasmic 300 
membrane and external outer membrane of Gram-negative bacteria) provides an oxidising 301 
environment which is more favourable for protein folding and disulphide bond formation 302 
(Baneyx and Mujacic, 2004). Therefore, the pFLAG-MAT-Tag-ATS vector was employed in 303 
an attempt to increase the yield of soluble protein. The pFLAG-MAT-Tag-ATS vector encodes 304 
the outer membrane protein A signal peptide (OmpA) and incorporation of this sequence at the 305 
N-terminus targets recombinant protein to the periplasm, where the OmpA is cleaved by signal 306 
peptidase as the recombinant protein crosses the bacterial inner cytoplasmic membrane (Freudl 307 
et al., 1987). Western blot analysis of periplasmic preparations, isolated for use in downstream 308 
assays demonstrated the molecular weight differences between the different rcINS proteins 309 
(Fig. 3). 310 
 311 
Receptor-binding assays were developed to assess the different SCI analogues against 312 
rhINSR and rhIGF-1R, with biotinylated insulin and IGF-1 used as control ligands. Although 313 
human recombinant receptors were used, this was considered appropriate since canine IGF-12 314 
and human IGF-13 share an identical sequence and canine insulin4 and human insulin5 differ 315 
by only one amino acid in the B chain (B30A/T). However, it should be noted that these studies 316 
                                                 
2 See: http://www.uniprot.org/uniprot/P33712  
3 See: http://www.uniprot.org/uniprot/Q9NP10  
4 See: http://www.uniprot.org/uniprot/P01321  
5 See: http://www.uniprot.org/uniprot/P01308  
were undertaken with heterologous receptors, which might not represent the situation with 317 
autologous canine receptors. Initial studies established the working range of the assays with a 318 
receptor concentration of 2–4 µg/mL found to be optimal, resulting in sensitivity for ligand 319 
binding down to approximately 0.1 nM. It was important to assess binding to rhIGF-1R as well 320 
as to rhINSR, since an insulin analogue might have the potential for increased affinity, resulting 321 
from changes to the peptide sequence, with subsequent mitogenic activity and increased 322 
oncogenic potential (Vajo et al., 2001). 323 
 324 
Detection using anti-FLAG antibody confirmed that all SCI analogues were able to 325 
bind to both rhINSR and rhIGF-1R. Binding of rcPROINS to rhINSR resulted in a significantly 326 
weaker signal compared to each of the SCI analogues, suggesting lower affinity for the 327 
receptor. This is consistent with other studies, which demonstrate that proinsulin has relative 328 
affinity of 1–2% for INSR compared to insulin (Lee et al., 2000). There was no significant 329 
difference in signal for rhINSR binding comparing the different SCI analogues. Incubation 330 
with rhIGF-1R gave significantly reduced signals for rcPROINS and for each SCI analogue, 331 
compared to binding to rhINSR, and there was no significant difference in rhIGF-1R signal 332 
within the rcPROINS/rcINS group. 333 
 334 
The results of the receptor-binding assays suggest that all SCI analogues demonstrate 335 
greater affinity for the rhINSR than for the rhIGF-1R, with rcINS[GGGPGKR] and 336 
rcINS[hIGF-2C] showing relative binding similar to that demonstrated by insulin. Using a 337 
competitive-inhibition ELISA against INSR, the rcINS[GGGPGKR] analogue demonstrated 338 
the highest relative affinity (IC50 = 187 pM), followed by rcINS[cIGF-2C] (IC50 = 593 pM) and 339 
rcINS[cIGF-2C] (IC50 = 613 pM). It was not possible to calculate IC50 for rcPROINS since 340 
sufficient inhibition could not be achieved, even using a concentration of 20 nM. This indicates 341 
that each of the SCI analogues showed much greater affinity than rcPROINS. The two 342 
insulin/IGF-2 C-peptide chimaeric proteins demonstrated similar relative affinity for rhINSR, 343 
which is unsurprising since they differ by only two residues (Fig. 1B). 344 
 345 
There are several other studies describing binding characteristics of SCI analogues. Lee 346 
et al. (2000), who developed a human SCI analogue containing the GGGPGKR linker, 347 
compared its receptor binding with both insulin and proinsulin, reporting an affinity for the 348 
INSR of 28% compared to native insulin, and 1350% that of proinsulin. In a more recent study 349 
investigating over 30 different SCI analogues, it was concluded that intermediate linking 350 
peptides of 7-10 residues, composed primarily of glycine residues (to promote molecular 351 
flexibility) along with a C-terminal arginine, demonstrate the greatest INSR affinities and 352 
bioactivity (Rajpal et al., 2009). Indeed, a SCI analogue with a hexapeptide linking sequence 353 
(GGGPRR) has demonstrated enhanced INSR affinity of 130% compared to native insulin, 354 
although in that particular molecule the A8:threonine residue was also replaced with histidine 355 
(Hua et al., 2008). 356 
 357 
We are not aware of any studies that have investigated SCI analogues based on the 358 
concept of an insulin/IGF-2 C-peptide chimaera, although there has been a report of an 359 
insulin/IGF-1 C-peptide chimaera (Kristensen et al, 1995). The binding affinity for that 360 
molecule compared favourably with insulin, and was reported to be between 55-94%. This was 361 
surprising since the presence of the linking peptide was predicted to limit the flexibility of the 362 
insulin domains necessary for receptor binding, and it was also expected to impair the 363 
important A1:glycine residue essential for receptor binding (Pullen et al., 1976). It was 364 
proposed that the C-peptide of IGF-1 interacted directly with a conserved domain in the INSR 365 
since this receptor and the IGF-1R are similar. This is unlikely to be the case with an 366 
insulin/IGF-2 C-peptide chimaera since the IGF-2R belongs to a functionally different receptor 367 
class. 368 
 369 
In glucose uptake assays, adipocytes derived from 3T3-L1 cells incubated with porcine 370 
insulin, rcINS[GGGPGKR], rcINS[cIGF-2C] or rcINS[hIGF-2C] all resulted in significantly 371 
higher fluorescence (suggesting GLUT4 mediated 6-NBDG uptake) compared to unstimulated 372 
cells. All SCI analogues resulted in comparable 6-NBDG uptake, which was significantly 373 
greater than that seen with rcPROINS. This indicates that substitution of the proinsulin C-374 
peptide for the various linker peptides resulted in biologically-active molecules. 375 
 376 
Conclusions 377 
The present study has demonstrated that it is possible to produce recombinant canine 378 
SCI analogues that are capable of INSR binding and stimulating glucose uptake in cells, 379 
without the need for post-translational processing. This work paves the way for production of 380 
recombinant canine insulin analogues that could be scaled up, with a view to developing novel 381 
therapeutics for canine diabetes. 382 
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Figure legends 485 
 486 
Fig. 1. (A) Post-translational modification of proinsulin to yield the biologically-active insulin 487 
and C-peptide. (B) Details of single chain insulin analogues adapted from recombinant canine 488 
proinsulin (rcPROINS) for the present study. Three different recombinant canine insulin 489 
analogues (rcINS) were generated, where the insulin C-peptide was substituted with different 490 
linking peptide sequences. 491 
 492 
 493 
Fig. 2. Detection of FLAG-tagged recombinant protein. BL-21(T1) Escherichia coli were 494 
transformed with each rcINS construct in one of two expression vectors. After induction of 495 
expression, bacterial lysates were prepared and analysed by ELISA, using nickel-coated plates 496 
to capture proteins expressing a metal-affinity tag and detected using an anti-FLAG antibody. 497 
Absorbance is shown as the mean  standard error of the mean (SEM) of triplicate wells 498 
following subtraction of background (lysis buffer only). Negative control is lysate from 499 
bacteria transformed with wild-type pTAC-MAT-Tag-2 plasmid DNA. Positive control is lysate 500 
from bacteria transformed with pFLAG-MAT-Tag-ATS+BAP. The experiment was repeated 501 
with similar results. 502 
503 
 504 
Fig. 3. Western blotting of FLAG-tagged rcINS isolated from bacterial periplasmic fractions. 505 
BL-21 (T1) Escherichia coli were transformed with pFLAG-MAT-Tag-ATS plasmid DNA 506 
containing the indicated constructs. After induction of expression, bacteria were subjected to 507 
osmotic lysis and periplasmic samples analysed by Western blotting, using an anti-FLAG 508 
antibody, detected by enhanced chemiluminescence. The negative control (-) is from bacteria 509 
transformed with wild-type pTAC-MAT-Tag-2 vector and the positive control (+) is from 510 
bacteria transformed with pFLAG-MAT-Tag-ATS+BAP (anticipated size of bacterial alkaline 511 
phosphatase ~50kDa). M, molecular weight marker. 512 
 513 
Fig. 4. (A) Binding of rcINS constructs to INSR and IGF-1R. ELISA wells were coated with 4 514 
µg/mL rhINSR or rhIGF-1R. Biotinylated bovine insulin, biotinylated human IGF-1 or 515 
periplasmic fractions of the indicated constructs (all 5 nM) were added and binding detected 516 
using either streptavidin-HRP or anti-FLAG HRP antibody. Absorbance is shown as the mean 517 
 standard error of the mean (SEM) of triplicate wells. (B) Dose-response curve for binding of 518 
rcINS constructs to INSR. (C) Competition-ELISA for binding of rcINS constructs to INSR. 519 
Increasing concentrations of rcINS protein were co-cultured in rhINSR coated plates in the 520 
presence of 3 nM biotinylated bovine insulin, with binding detected using streptavidin-HRP. 521 
  522 
 523 
Fig. 5. Assessment of insulin-stimulated glucose uptake in 3T3-L1 adipocytes. 3T3-L1 524 
adipocytes were serum-starved in low-glucose DMEM for 2 h prior to incubation with 525 
fluorescent glucose analogue 6-NBDG for 1 h in the presence of 5 nM porcine insulin, 526 
recombinant canine proinsulin (rcPROINS) or the indicated recombinant canine insulin 527 
analogues. Cells were lysed and fluorescence measured (λex = 466 nm, λem = 540 nm, cut-off 528 
= 530 nm). Results represent the mean of triplicate samples  SEM. The Student’s t test was 529 
used to compare fluorescence of stimulated cells to unstimulated cells (* P <0.05) and to 530 
compare recombinant insulin analogues to rcPROINS († P <0.05). 531 
532 
Appendix: Supplementary Table 1 533 
 534 
Restriction endonuclease sites shown underlined; coding sequences in bold refer to explanation in target 535 
column. 536 
 537 
Primer name Target Primer sequence Amplicon length (bp) 
PROINS pTACMAT EcoRI/SphI Canine proinsulin coding sequence with 
additional restriction site EcoRI for cloning 
For: GAATTCGTTAACCAGCACCTG 268 
Canine proinsulin coding sequence with 
additional restriction site SphI for cloning 
Rev: GCATGCCGTTGCAGTAATTCTCCAG 
INS A CORE Amplification of canine insulin A chain. Used 
with PROINS pTACMAT SphI REV. 
For: GGCATCGTGGAGCAGTGC 70 
INS B CORE Amplification of canine insulin B chain. Used 
with PROINS pTACMAT EcoRI FOR 
Rev: GGCCTTAGGCGTGTAGAAG 93 
INS A LINK Modified INS A CORE primer to generate 
synthetic linker sequence (in bold). Contains 
XmaI restriction site. Used with PROINS 
pTACMAT SphI REV 
For: CCCGGGTAAGAGAGGCATCGTGGAGCAGTGC 83 
INS B LINK Modified INS B CORE primer to generate 
synthetic linker sequence (in bold). Contains 
XmaI restriction site. Used with PROINS 
pTACMAT EcoRI FOR 
Rev: ATACCCGGGCCACCACCTGCCTTAGGCGTGTAG 110 
INSA cIGF2C Amplification of canine insulin A chain and 
part of canine IGF-2 C peptide (in bold). 
Contains BglII site. Used with PROINS 
pTACMAT SphI REV 
For: AGATCTAGCCGTGGCATCGTGGAGCAGTGC 82 
INSB cIGF2C Amplification of canine insulin B chain and 
part of canine IGF-2 C peptide (in bold). 
Contains BglII site. Used with PROINS 
pTACMAT EcoRI FOR 
Rev: GATCTGCGAGTTACGCGAGAGGCCTTAGGCGTGTAGAAG 113 
INSA hIGF2C Amplification of canine insulin A chain and 
part of human IGF-2 C peptide (in bold). 
Contains XbaI site.Used with PROINS 
pTACMAT SphI REV 
For: TCTAGACGCAGCCGTGGCATCGTGGAGCAGTGC 85 
INSB hIGF2C Amplification of canine insulin B chain and 
part of human IGF-2 C peptide (in bold). 
Contains XbaI site. Used with PROINS 
pTACMAT EcoRI FOR 
Rev: GATCTAGACACGCGGCTGGCCTTAGGCGTGTAGAAG 110 
 538 
For, forward; Rev, reverse; bp, base pairs. 539 
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Separate coding sequences for canine insulin A-chain and B-chain were generated by PCR, using pSC-A/rcPROINS pDNA as template. The reverse primer for the insulin 
B chain, and the forward primer for the insulin A-chain incorporated the additional coding sequence for the synthetic peptide linker (GGGPGKR) as well as for XmaI, to 
facilitate ligation.  
 
 
PCR product for insulin B-chain + synthetic peptide linker (INSB/GGG) coding sequence (110 bp). Primer pair: PROINS pTACMAT EcoRI For/ INS B LINK Rev 








PCR product for synthetic peptide linker + insulin A-chain (PKGR/INSA) coding sequence (83 bp). Primer pair: INS A LINK For/ PROINS pTACMAT SphI Rev 












......TTCTACACGCCTAAGGCAGGTGGTGGC       CCGGGTAAGAGAGGCATCGTGGAGCAGTGCTGC...... 












Suppl Fig. 1. Generation of rcINS/ synthetic peptide linker (rcINS[GGGPGKR]) 
Coding sequences for insulin B-chain highlighted in blue, for linking peptide sequence in black, and for insulin A-chain highlighted in red. Non-coding sequences are not highlighted. Primer 
binding sites are shown underlined. Restriction sites shown in green. Primer sequences are given in Supplementary Table 1. 







Oligonucleotides coding for FLAG® epitope with added bases for HindIII / EcoRI restriction sites when dimerised: 
 
 
FLAG® oligo For :  5’-AGCTAGACTACAAGGACGACGATGACA-3’ 
 





FLAG® dimer:         AGCTAGACTACAAGGACGACGATGACA 
                       TCTGATGTTCCTGCTGCTACTGTTTAA 






















ATGA     AGCTAGACTACAAGGACGACGATGACA     AATTCGTTAACCAGCACCTGT…… 
















Suppl. Fig. 2. Schematic illustrating insertion of FLAG® coding sequence into pTAC-MAT-Tag®-2/rcPROINS and 
pTAC-MAT-Tag®-2/rcINS[GGGPGKR] 
FLAG oligonucleotides were annealed to form a dimer and then ligated into the pTAC-MAT-Tag®-2 vector containing 
rcPROINS or rcINS[GGGPGKR] which had been digested with HindIII and EcoRI.  Recognition sites shown in green, start 
codon in red.  
 
 









Mutated HindIII site 




Separate coding sequences for canine insulin A-chain and B-chain were generated by PCR, using pSC-A/rcPROINS or pTAC-MAT-Tag®-2/FLAG®-rcPROINS pDNA 
respectively as template. The reverse primer for the insulin B chain, and the forward primer for the insulin A-chain incorporated the additional coding sequence for the 
canine IGF-2 C-peptide (cIGF-2C) as well as for BglII, to facilitate ligation.  
 
PCR product for insulin B-chain + canine IGF-2 C-peptide coding sequence incorporating the FLAG® epitope (141 bp). Primer pair: FLAG® For/ INS B cIGF2C Rev  






PCR product for canine IGF-2 C-peptide + insulin A-chain coding sequence (82 bp). Primer pair: INS A cIGF2C For/ PROINS pTACMAT SphI Rev 













......TTCTACACGCCTAAGGCCTCTCGCGTAACTCGCA      GATCTAGCCGTGGCATCGTGGAGCAGTGCTGC...... 












Suppl. Fig. 3. Generation of rcINS/ canine IGF-2 C-peptide chimaera (rcINS[cIGF2-C]) 
Coding sequences for insulin B-chain highlighted in blue, for linking peptide sequence in black, and for insulin A-chain highlighted in red. FLAG® epitope coding sequence highlighted in 
yellow. Non-coding sequences are not highlighted. Primer binding sites are shown underlined. Restriction sites shown in green. Primer sequences are given in Supplementary Table 1.   







Separate coding sequences for canine insulin A-chain and B-chain were generated by PCR, using pSC-A/rcPROINS or pTAC-MAT-Tag®-2/FLAG®-rcPROINS pDNA 
respectively as template. The reverse primer for the insulin B chain, and the forward primer for the insulin A-chain incorporated the additional coding sequence for the 
human IGF-2 C-peptide (hIGF-2C) as well as for XbaI, to facilitate ligation.  
 
 
PCR product for insulin B-chain + human IGF-2 C-peptide coding sequence incorporating the FLAG® epitope (135 bp). Primer pair: FLAG® For/ INS B hIGF2C Rev 






PCR product for human IGF-2 C-peptide + insulin A-chain coding sequence (85 bp). Primer pair: INS A hIGF2C/ PROINS pTACMAT SphI Rev 












......TTCTACACGCCTAAGGCCAGCCGCGTGT      CTAGACGCAGCCGTGGCATCGTGGAGCAGTGCTGC...... 














Suppl. Fig. 4. Generation of rcINS/ human IGF-2 C-peptide chimaera (rcINS[hIGF2-C]) 
Coding sequences for insulin B-chain highlighted in blue, for linking peptide sequence in black, and for insulin A-chain highlighted in red. FLAG® epitope coding sequence highlighted in 
yellow. Non-coding sequences are not highlighted. Primer binding sites are shown underlined. Restriction sites shown in green. Primer sequences are given in Supplementary Table 1. 











Suppl Fig. 5 Murine fibroblasts were differentiated into adipocytes 
Murine fibroblasts (3T3-L1) were seeded at a density of 1 x 105 cells per well in 24-well tissue culture plates. After growing to confluency in DMEM/ 10% bovine calf serum, cells 
were cultured for another 48 h before induction of adipogenesis was induced with insulin, IBMX and dexamethasone in DMEM/ 10% FBS (day 0). Adipocyte differentiation was 
usually complete by day 8. Oil Red O/ haematoxylin staining, x200.  
(a) 3T3-L1 preadipocytes demonstrated a fibroblast-like morphology 2 d after seeding. 
(c) Day 8: 3T3-L1 cells had an adipocyte like morphology with much more rounded 
cytoplasm full of lipid droplets stained red with Oil Red O 
(b) Day 0: 48 h after cells became 100% confluent, usually 5-6 days after seeding. 
(d) Day 8: 3T3-L1 cells which were not stimulated with insulin, IBMX and 
dexamethasone. There was approximately 1 differentiated cell/ hpf.   
 
(a) (b) 
(c) (d) 
